Cvs Health Tablet, Chewable
NDC Package 69842-423-42

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Cvs Health (sodium citrate dihydrate) tablets is ▪Adults: 2-4 tablets.▪Children: Consult a doctor for appropriate dosage.▪Chew tablets completely.▪Dosage may be repeated after 15 minutes, not to exceed 24 tablets in a 24-hour period unless advised by a doctor.▪Read all package directions and warning before use and use only as directed.▪These tablets are intended for use by normally healthy persons only.▪Persons under 18 years of age should use only as directed by a doctor. This formulation utilizes a tablet, chewable delivery system. Marketed by Cvs Pharmacy,inc., this product is identified by NDC 69842-423.

Identification & Billing

NDC Package Code
69842-423-42
Package Description
3 BLISTER PACK in 1 CARTON / 14 TABLET, CHEWABLE in 1 BLISTER PACK
Product Code
11-Digit Billing Format
69842042342
RxNorm Crosswalk
RxCUI: 2002800 - sodium citrate 230 MG Chewable Tablet

Clinical Specifications

Proprietary Name
Cvs Health Nausea Relief
Non-Proprietary Name
Sodium Citrate Dihydrate
Substance Name
Trisodium Citrate Dihydrate
Dosage Form
Tablet, Chewable - A solid dosage form containing medicinal substances with or without suitable diluents that is intended to be chewed, producing a pleasant tasting residue in the oral cavity that is easily swallowed and does not leave a bitter or unpleasant after-taste.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
▪Adults: 2-4 tablets.▪Children: Consult a doctor for appropriate dosage.▪Chew tablets completely.▪Dosage may be repeated after 15 minutes, not to exceed 24 tablets in a 24-hour period unless advised by a doctor.▪Read all package directions and warning before use and use only as directed.▪These tablets are intended for use by normally healthy persons only.▪Persons under 18 years of age should use only as directed by a doctor.

Regulatory & Marketing

Labeler Name
Cvs Pharmacy,inc.
Product Type
Human Otc Drug
Marketing Category
UNAPPROVED DRUG OTHER - An unapproved drug product in a marketing category that is not reflected on a particular list.
Start Marketing Date
05-22-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 69842-423-42 identifies a specific commercial package of 3 blister pack in 1 carton / 14 tablet, chewable in 1 blister pack of Cvs Health Nausea Relief, a human over the counter drug labeled by Cvs Pharmacy,inc.. This tablet, chewable is formulated for oral use and contains trisodium citrate dihydrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cvs Pharmacy,inc. on May 22, 2019. The current certification is valid through December 31, 2026.

How is this Cvs Pharmacy,inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 69842042342. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
69842-423-42
11-Digit CMS (5-4-2)
69842-0423-42

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.